Trial to Examine the Effect of Natural Anti- Obesity Agent (Phaseolus Vulgaris) Among Women of Lahore

NCT ID: NCT05451927

Last Updated: 2024-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-27

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This double-blind randomized placebo-controlled trial will test the hypothesis that administration of Phaseolus Vulgaris supplementation to women in Lahore, Pakistan, who are overweight will induce the weight loss (Primary outcome) and changes in body composition (Waist circumference) secondary outcome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight and Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phaseolus Vulgaris

Three oral doses of 1000 mg Phaseolus Vulgaris daily for 3 months

Group Type EXPERIMENTAL

Phaseolus Vulgaris

Intervention Type DIETARY_SUPPLEMENT

Weight loss

Placebo

Three oral doses of Placebo daily for 3 months

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Phaseolus Vulgaris

Weight loss

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI ranges from 25-40
* Consistently stable body weight for at least 6 months
* Good general health
* No ongoing drug treatment for weight reduction
* Commitment to avoid any changes in lifestyle throughout the test period
* Age between 18-45 years
* Women resident of Lahore

Exclusion Criteria

* Pregnant or breast-feeding females
* People with Type 2 diabetes
* People with any other chronic diseases
* Weight reduction treatment during the 6 months prior to the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of the Punjab

OTHER

Sponsor Role collaborator

Hafiza Aisha Sadiqa

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hafiza Aisha Sadiqa

Student

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aisha Sadiqa, M.Phil

Role: PRINCIPAL_INVESTIGATOR

University of the Punjab

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Akhuwat Medical Centre

Lahore, Punjab Province, Pakistan

Site Status

Niazi Medical Centre

Lahore, Punjab Province, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RCT012022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of HRS9531 Tablet in Obese Subjects
NCT06841445 ACTIVE_NOT_RECRUITING PHASE2
One-Year Study of S1B-509 vs Placebo for Weight Loss
NCT06517797 NOT_YET_RECRUITING PHASE2